Literature DB >> 28734158

Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.

Li Peng1, Jun Liu1, Liuan Qin1, Jia Liu1, Shaozhi Xi1, Caiyi Lu2, Tong Yin3.   

Abstract

BACKGROUND: Both platelet-derived microRNAs and the genotype of CYP2C19*2 were implicated for the variability of clopidogrel antiplatelet responsiveness. However, their interaction on the antiplatelet responsiveness of clopidogrel in patients with acute coronary syndrome (ACS) remains unknown.
METHODS: Consecutive clopidogrel-treated patients with ACS were recruited, with their antiplatelet responsiveness evaluated by the relative platelet inhibition (RI), as measured by light transmittance aggregometry (LTA) at baseline and 5days' after the maintenance treatment of clopidogrel. Extreme cases were selected according to the octiles of RI value. Expression of the microRNAs targeting the mRNAs of P2RY12 was analyzed in the platelet of the extreme cases. Genotyping of CYP2C19*2 was performed for each extreme case.
RESULTS: Among the included 272 ACS patients, 21 cases were screened as the extremely high-responders with RI>84%, and 18 as the extremely low-responders with RI<10%. Bioinformatics tools predicted the candidate microRNAs of miR-223, miR-221, and miR-21 could bind directly to the mRNA of P2RY12. Compared with the extremely low-responders, the expression of miR-223, miR-221, and miR-21 was significantly higher in the extremely high-responders (miR-223: 7.18±2.95 vs. 0.99±0.64, p=0.022; miR-221: 3.60±2.54 vs. 1.14±0.81, p=0.004; miR-21: 4.36±3.33 vs. 2.31±1.69, p=0.01). ROC curve showed ideal discriminatory power of the platelet-derived miRNAs for the prediction of clopidogrel antiplatelet responsiveness (c-index=0.70 for miR-223; c-index=0.76 for miR-221; c-index=0.79 for miR-21). After stratified by the carrier status of CYP2C19*2, the association between platelet-derived miRNAs and clopidogrel antiplatelet responsiveness could be found only in CYP2C19*2 carriers, but not in non-carriers.
CONCLUSIONS: Platelet-derived miRNAs (miR-223, miR-221 and miR-21) are independently associated with clopidogrel antiplatelet responsiveness in ACS patients. However, the association could be influenced by the interaction with CYP2C19*2 genotype.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; CYP2C19; Clopidogrel; MicroRNA; Platelet

Mesh:

Substances:

Year:  2017        PMID: 28734158     DOI: 10.1016/j.thromres.2017.07.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

Review 1.  Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases.

Authors:  Dan Li; Yujuan Li; Shengjie Yang; Zongliang Yu; Yanwei Xing; Min Wu
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

2.  Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition.

Authors:  Aitana Braza-Boïls; Temo Barwari; Clemens Gutmann; Mark R Thomas; Heather M Judge; Abhishek Joshi; Raimund Pechlaner; Manu Shankar-Hari; Ramzi A Ajjan; Ian Sabroe; Robert F Storey; Manuel Mayr
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

3.  Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI.

Authors:  Qifeng Zhang; Zhixiong Zhong; Bin Li; Zhengxian Liao; Pingsen Zhao; Zhuolian Ye; Xuebo He; Hao Wang; Wenhao Chen; Junping Huang
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

Review 4.  microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring.

Authors:  Teresa L Krammer; Manuel Mayr; Matthias Hackl
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

Review 5.  MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review.

Authors:  Pamela Czajka; Alex Fitas; Daniel Jakubik; Ceren Eyileten; Aleksandra Gasecka; Zofia Wicik; Jolanta M Siller-Matula; Krzysztof J Filipiak; Marek Postula
Journal:  Front Physiol       Date:  2021-04-15       Impact factor: 4.566

6.  Influence of GAS5/MicroRNA-223-3p/P2Y12 Axis on Clopidogrel Response in Coronary Artery Disease.

Authors:  Yan-Ling Liu; Xiao-Lei Hu; Pei-Yuan Song; He Li; Mu-Peng Li; Yin-Xiao Du; Mo-Yun Li; Qi-Lin Ma; Li-Ming Peng; Ming-Yu Song; Xiao-Ping Chen
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

Review 7.  Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring.

Authors:  Grzegorz Procyk; Dominika Klimczak-Tomaniak; Grażyna Sygitowicz; Mariusz Tomaniak
Journal:  J Clin Med       Date:  2022-03-22       Impact factor: 4.241

8.  Dissecting miRNA-Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine.

Authors:  Fani Chatzopoulou; Konstantinos A Kyritsis; Christos I Papagiannopoulos; Eleftheria Galatou; Nikolaos Mittas; Nikoleta F Theodoroula; Andreas S Papazoglou; Efstratios Karagiannidis; Maria Chatzidimitriou; Anna Papa; Georgios Sianos; Lefteris Angelis; Dimitrios Chatzidimitriou; Ioannis S Vizirianakis
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

9.  Methods to Investigate miRNA Function: Focus on Platelet Reactivity.

Authors:  Alix Garcia; Sylvie Dunoyer-Geindre; Richard J Fish; Marguerite Neerman-Arbez; Jean-Luc Reny; Pierre Fontana
Journal:  Thromb Haemost       Date:  2020-10-29       Impact factor: 5.249

10.  MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus.

Authors:  Justyna Pordzik; Ceren Eyileten-Postuła; Daniel Jakubik; Pamela Czajka; Anna Nowak; Salvatore De Rosa; Aleksandra Gąsecka; Agnieszka Cieślicka-Kapłon; Piotr Sulikowski; Krzysztof J Filipiak; Dagmara Mirowska-Guzel; Jolanta M Siller-Matula; Marek Postuła
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.